{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:26:28Z","timestamp":1794317188950,"version":"4.9.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.022","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:06:03Z","timestamp":1792080363000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive, Simplified, and Objective Comorbidity Assessment before Allogeneic Hematopoietic Cell Transplantation: A Comparative Cohort Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3165-1899","authenticated-orcid":false,"given":"Lorenzo","family":"Iovino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Glockling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-1807","authenticated-orcid":false,"given":"Ryan","family":"Basom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-2159","authenticated-orcid":false,"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5680-8688","authenticated-orcid":false,"given":"Marco B.","family":"Mielcarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-9739","authenticated-orcid":false,"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian \u201cVicky\u201d","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5260-1981","authenticated-orcid":false,"given":"Mohamed L.","family":"Sorror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.10.022_bib0001","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.beha.2018.09.011","article-title":"Why is a 3-year NRM following allogeneic transplantation still stuck at approximately 20%?","volume":"31","author":"Barrett","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2026.10.022_bib0002","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.022_bib0003","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbmt.2009.02.007","article-title":"Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences","volume":"15","author":"Sorror","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.022_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.11.019","article-title":"Adapting the HCT-CI definitions for children, adolescents, and young adults with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation","volume":"29","author":"Friend","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.022_bib0005","doi-asserted-by":"crossref","first-page":"125.e121","DOI":"10.1016\/j.jtct.2022.11.020","article-title":"Expanded HCT-CI definitions capture comorbidity better for younger patients of allogeneic HCT for nonmalignant diseases","volume":"29","author":"Broglie","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.022_bib0006","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.bbmt.2015.04.002","article-title":"Design and validation of an augmented hematopoietic cell transplantation-comorbidity index comprising pretransplant ferritin, albumin, and platelet count for prediction of outcomes after allogeneic transplantation","volume":"21","author":"Vaughn","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.022_bib0007","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2021004319","article-title":"The simplified comorbidity index: a new tool for prediction of nonrelapse mortality in allo-HCT","volume":"6","author":"Shouval","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.10.022_bib0008","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjh.19055","article-title":"The simplified comorbidity index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation","volume":"203","author":"Elias","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.10.022_bib0009","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.022_bib0010","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.022_bib0011","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jtct.2021.02.030","article-title":"Impact of pretransplantation renal dysfunction on outcomes after allogeneic hematopoietic cell transplantation","volume":"27","author":"Farhadfar","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.022_bib0012","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2024027543","article-title":"Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"145","author":"Wuliji","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.022_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030515","article-title":"Development and validation of a concise objectifiable risk evaluation score for non-relapse mortality after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Weise","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:48:01Z","timestamp":1794314881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726008122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":13,"alternative-id":["S2666636726008122"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive, Simplified, and Objective Comorbidity Assessment before Allogeneic Hematopoietic Cell Transplantation: A Comparative Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}